Failed apnea reduction · treatment of apnea
Doxapram showed no clear difference in 1a. Failed apnea reduction after 2–7 days – doxapram compared to no… compared with no treatment, placebo, methylxanthine (including theophylline,… (low certainty).
3 findings from 1 review
RR 0.45 [0.2, 1.05]
1 study · 21 participants
Low
RR 1.35 [0.53, 3.45]
4 studies · 84 participants
Very low
RR 0.08 [0.01, 1.17]
1 study · 10 participants
Very low
4b. Death at any time during initial hospitalization – doxapram compared to alternative treatment for the treatment of apnea · treatment of apnea
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
5c. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the treatment of apnea · treatment of apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
side‐effects ‐ side‐effects causing abandon · treatment of apnea
3 findings from 1 review
1c.'Clinical apnea' after initiation of treatment – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation
Doxapram may leads to lower 1c.'Clinical apnea' after initiation of treatment – doxapram as an… compared with no treatment, placebo, methylxanthine (including theophylline,… (low certainty).
1 finding from 1 review
2c. Failed apnea reduction after 2–7 days – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation
Doxapram showed no clear difference in 2c. Failed apnea reduction after 2–7 days – doxapram as an adjunct… compared with no treatment, placebo, methylxanthine (including theophylline,… (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · prevention of reintubation
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
4a.Death at any time during initial hospitalization – doxapram compared to no treatment for the treatment of apnea · prevention of reintubation
It is very uncertain whether doxapram changes 4c. Death (at any time during initial hospitalization) – doxapram as… compared with no treatment, placebo, methylxanthine (including theophylline,… (very low certainty).
1 finding from 1 review
5c. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
side‐effects ‐ side‐effects causing abandon · prevention of reintubation
The review found no eligible studies for this question.
2 findings from 1 review
Positive‐pressure ventilation after institution of treatment · treatment of apnea
It is very uncertain whether doxapram changes 2a. Need for positive pressure ventilation after initiation of… compared with no treatment, placebo, methylxanthine (including theophylline,… (very low certainty).
3 findings from 1 review
Chronic lung disease · treatment of apnea
The review found no eligible studies for this question.
3 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Serious adverse events or adverse events Death due to methadone use · individuals dependent on illicit opiates
1 finding from 1 review
Bone metastases · women with advanced breast cancer without bone metastases
Bisphosphonates showed no clear difference in bone metastases compared with placebo/observation (moderate certainty).
1 finding from 1 review
Duration of sensory block (we included all studies describing duration of sensory block regardless of how it was described) · participants undergoing surgery with peripheral nerve block
1 finding from 1 review
Incidence of serious adverse events (we used the NIH definition of adverse events. A serious event includes death, a life‐threatening event that requires hospitalization or prolonged hospitalization, disability or congenital anomaly) · participants undergoing surgery with peripheral nerve block
1 finding from 1 review
Postoperative pain intensity in the immediate postobturation period (up to 72 hours), continuous (VAS) · participants undergoing surgery with peripheral nerve block
3 findings from 1 review
no estimate extracted
5 studies · 257 participants
Very low
no estimate extracted
9 studies · 469 participants
Low
no estimate extracted
3 studies · 296 participants
Low
Inattention Measured using SNAP‐IV inattention subscale (range 0 to 27) · Children aged 6 to 18 years with ASD
2 findings from 1 review
Impulsivity · Children aged 6 to 18 years with ASD
2 findings from 1 review
Hyperactivity · Children aged 6 to 18 years with ASD
2 findings from 1 review